According
to a new research report “Global
Bromodomain and Extra-Terminal (BET) Inhibitors Pipeline Analysis, 2017 -
Clinical Trials & Results, Patent, Designation, Collaboration, and Other
Developments”, published by P&S Market Research, BET
inhibitors currently exhibit a strong pipeline with estimated 38 drug
candidates.
Browse
the Report Summary at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis
The study
analyzed that the BET
inhibitors pipeline comprised 38 drug
candidates in different stages of development.
As per
the findings of the research, most of the BET inhibitor pipeline drug
candidates are being developed to be administered by oral route.
In BET inhibitors, IC50 value is measured as the
concentration of drug at which 50% of the target is inhibited. IC50 is a
pharmacokinetic measure; the lower the IC50 of drug candidate, the lesser the
desired effect, and the less likelihood of the drug to have some off-target
effect. Kd is known as dissociation constant of drug. It measures the rate of
dissociation of the drug and its binding affinity. Birabresib (MK8628), a BET
inhibitor by Merck & Co., has IC50 value of 100nM.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis/report-sample
The research finds that different companies are
collaborating for the development of BET inhibitors. In January 2017,
ConverGene had entered into a sponsored research agreement with the University
of Maryland, Baltimore to investigate the in vivo anti-leukemic effects of
ConverGene’s lead BET inhibitor drug candidates, CG223 and CG250.
Some of the key players
developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc,
Bristol-Myers Squibb Company, and others.
No comments:
Post a Comment